|30.68||-1.35||-4.21%||Vol 200.21K||1Y Perf -26.51%|
|Sep 24th, 2021 16:00 DELAYED|
|- -||- -%|
|Target Price||101.38||Analyst Rating||Strong Buy 1.00|
|Potential %||230.44||Finscreener Ranking||— -|
|Insiders Trans % 3/6/12 mo.||-100/-100/-100||Value Ranking||— -|
|Insiders Value % 3/6/12 mo.||-100/-100/-100||Growth Ranking||— -|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-100||Income Ranking||— -|
|Price Range Ratio 52W %||17.04||Earnings Rating||Buy|
|Market Cap||858.09M||Earnings Date||11th Nov 2021|
Today's Price Range
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||11th Nov 2021|
|Estimated EPS Next Report||-1.08|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||242.64K|
|Avg. Monthly Volume||270.24K|
|Avg. Quarterly Volume||345.53K|
BioXcel Therapeutics Inc. (NASDAQ: BTAI) stock closed at 30.68 per share at the end of the most recent trading day (a -4.21% change compared to the prior day closing price) with a volume of 200.22K shares and market capitalization of 858.09M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 40 people. BioXcel Therapeutics Inc. CEO is Vimal Mehta.
The one-year performance of BioXcel Therapeutics Inc. stock is -26.51%, while year-to-date (YTD) performance is -33.59%. BTAI stock has a five-year performance of %. Its 52-week range is between 23.07 and 67.74, which gives BTAI stock a 52-week price range ratio of 17.04%
BioXcel Therapeutics Inc. currently has a PE ratio of -7.50, a price-to-book (PB) ratio of 3.21, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -56.17%, a ROC of -61.80% and a ROE of -61.67%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.
Of the last four earnings reports from BioXcel Therapeutics Inc., there were 0 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.08 for the next earnings report. BioXcel Therapeutics Inc.’s next earnings report date is 11th Nov 2021.
The consensus rating of Wall Street analysts for BioXcel Therapeutics Inc. is Strong Buy (1), with a target price of $101.38, which is +230.44% compared to the current price. The earnings rating for BioXcel Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
BioXcel Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
BioXcel Therapeutics Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 15.26, ATR14 : 1.72, CCI20 : 115.18, Chaikin Money Flow : -0.08, MACD : 0.87, Money Flow Index : 70.83, ROC : 6.31, RSI : 56.39, STOCH (14,3) : 59.27, STOCH RSI : 0.51, UO : 49.64, Williams %R : -40.73), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of BioXcel Therapeutics Inc. in the last 12-months were: Frank Yocca (Option Excercise at a value of $6 150), Frank Yocca (Sold 45 000 shares of value $2 318 540 ), Krishnan Nandabalan (Sold 473 250 shares of value $14 589 493 ), Richard I. Steinhart (Option Excercise at a value of $20 813), Richard I. Steinhart (Sold 3 750 shares of value $180 563 ), Vimal Mehta (Sold 473 250 shares of value $14 589 493 ), Vincent O'Neill (Option Excercise at a value of $136 650), Vincent O'Neill (Sold 75 000 shares of value $3 912 335 )
Wed, 11 Aug 2021 10:35 GMT Bioxcel Therapeutics (BTAI) Receives a Buy from H.C. Wainwright- TipRanks. All rights reserved.
Copyright © 2016-2021 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 67% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
This could take some time, please wait.